Physician profile
Ryan Milo Brown
NPI 1164865507
$2,748.87
in general payments reported to CMS, 2019-2025
21 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $219 · 2021: $388 · 2022: $941 · 2023: $450 · 2024: $101 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.03 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.27 | 2019-2025 | Ofev |
| Intuitive Surgical, INC. | $410.32 | 2022 | |
| Glaxosmithkline, LLC. | $367.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genzyme Corporation | $237.06 | 2019-2025 | |
| Grifols USA, LLC | $147.18 | 2020-2023 | Prolastin-C Liquid |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $103.19 | 2019-2024 | Airsupra, Breztri |
| Abbott Laboratories | $73.53 | 2024 | Amplatzer Amulet |
| Mylan Specialty L.P. | $70.06 | 2019-2023 | Yupelri |
| United Therapeutics Corporation | $70.03 | 2023 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $52.42 | 2020 | |
| Csl Behring | $39.14 | 2023 | Kcentra |
| Pharming Healthcare, INC. | $38.45 | 2023 | Ruconest |
| Nabriva Therapeutics, Plc | $37.18 | 2021 | |
| Genentech USA, INC. | $31.00 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.51 | 2022 | |
| Pfizer INC. | $19.12 | 2023 | |
| Mallinckrodt Hospital Products INC. | $18.00 | 2023 | Terlivaz |
| Insmed, INC. | $16.24 | 2025 | Arikayce |
| Gilead Sciences, INC. | $13.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.